Cyclosporin A efficacy and toxicity in organ transplantation with special focus on cadaveric renal transplantation.
The pharmacodynamic and pharmacokinetic properties of cyclosporin A are reviewed. Its adverse reactions and posology in allograft transplantation are described according to clinical experience. Preliminary results with the use of cyclosporin A (Cy A) in primary cadaveric renal transplant patients, in comparison to 3 other conventional treatments, are reported in a randomized study of 69 patients: even if graft acute tubular necrosis is more frequent in the Cy A group, this group is the one which reaches the most successful short term renal graft survival.
D000328:Adult; D002102:Cadaver; D002986:Clinical Trials as Topic; D003524:Cyclosporins / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000187:drug effects; D006400:Hematocrit; D006801:Humans; D007668:Kidney / Q000187:drug effects / Q000473:pathology; D016030:Kidney Transplantation; D007700:Kinetics
D003524:Cyclosporins